COVID-19 (CARES Act) Initiatives
Abstract
Originally accounted for separately under line of accounting USRE_030603680D8Z_COVID19, the COVID-19 (CARES Act) Initiatives leveraged federal, state, commercial, and academic members of the DoD Manufacturing Innovation Institute (MII) national ecosystem to begin execution of 13 projects through seven DoD MIIs in response to COVID-19. These projects support manufacture of antibody and antiviral diagnostics technologies, rapid deployment of medical devices and instrumentation, development of a range of medical countermeasures, and coordination of national efforts to accelerate secure U.S. manufacture and acceptance of critical medical supplies. Medical countermeasure projects include viral deactivation surface treatments, novel drug delivery systems, rapid production of personal protective equipment, manufacture of Natural Killer (NK) cells and virus-free red blood cells from stem cells, demand forecasting for allocation of critical medical supplies, and improving pharmaceutical industry capacity to optimize scale-up production using digital technology.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- 2c737d8b44b0c51ac793770c5f965915